The influence based on CYP3A5 gene polymorphism for calcineurin inhibitors for tailor-made treatment after living-donor liver transplantation.
Project/Area Number |
20591521
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | Mie University |
Principal Investigator |
USUI Masanobu Mie University, 大学院・医学系研究科, 講師 (10378341)
|
Co-Investigator(Kenkyū-buntansha) |
SUGIMOTO Kazushi 三重大学, 医学部附属病院, 助教 (60378370)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2008: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Keywords | 生体肝移植 / CYP3A5 / 遺伝子多型 / テーラーメード治療 / カルシニューリンインヒビター |
Research Abstract |
Pharmacokinetics of tacrolims in transplantation, especially a body-weight-based dose, often result in marked individual diversity of blood drug concentration. Tacrolimus is a substrate for cytochrome P450(CYP)3A5 having polymorphism. In this study, we genotyped CYP3A5 polymorphism and investigated the association between donor/recipient polymorphisms and pharmacokinetics of tacrolimus in living-donor liver transplantation (LDLT). Furthermore we are trying to introduce a tailor-made therapy based on the donor/recipient CYP3A5 polymorphisms. CYP3A5 polymorphism in the recipient as well as the donor highly influences pharmacokinetics of tacrolimus in the LDLT for the long term. Tailor-made treatment based on CYP3A5 genotype is effective to the reduction of the tacrolimus administration, which may reduce the incidence of drug side effect and ACR.
|
Report
(4 results)
Research Products
(33 results)
-
[Journal Article] J Hepatobiliary Pancreat Sci.2011
Author(s)
Mizuno S, Hamada T, Nakatani K, Kishiwada M, Usui M, Sakurai H, Tabata M, Sakamoto Y, Nishioka J, Muraki Y, Okuda M, Nobori T, Isaji S.
-
Journal Title
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Long-term influence of CYP3A5 donor/recipient polymorphism on the pharmacokinetics of calcineurin inhibitors in the recipients of living-donor liver transplantation2009
Author(s)
Usui M, Muraki Y, Kato H, Kuriyama N, Kishiwada M, Mizuno S, Sakurai H, Tabata M, Okuda M, Nishioka J, Nakatani A, Nobori T, Isaji S
Organizer
Transplant Congress
Place of Presentation
Boston, USA
Year and Date
2009-05-30
Related Report
-
-
-
-
-
-
-
-